Biotech

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) on Sunday announced new data from its clinical development program evaluating once-daily, oral investigational palsonify (paltusotine) in acromegaly. Acromegaly is a rare condition in adults that causes some bones, organs and other tissues to grow...

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) on Sunday presented new exploratory analyses from its Phase 2 PREVENT and Phase 2b trials of avexitide—an investigational GLP-1 receptor antagonist—at the Endocrine Society's annual meeting (ENDO 2025). The drug targets post-bariatric hypoglycemia (PBH),...

Bristol-Myers Squibb & Co. (NYSE:BMY) is gearing up to announce its second-quarter 2025 earnings on July 31, with expectations for adjusted earnings of $1.585 per share on sales of $11.31 billion, according to data from Benzinga Pro. While revenue and underlying earnings per share estimates for...

The U.S. Food and Drug Administration issued on Friday a Complete Response Letter for Ultragenyx Pharmaceutical Inc.’s (NASDAQ:RARE) Biologics License Application (BLA) for UX111 (ABO-102) AAV gene therapy for Sanfilippo syndrome type A (MPS IIIA).  In the CRL, the FDA requested that the...

Sonnet BioTherapeutics Inc. (NASDAQ:SONN) stock surged Monday amid high trading volume following news of a transformative business combination with Rorschach I, backed by Atlas Merchant Capital and Paradigm. The deal will create Hyperliquid Strategies Inc., a public cryptocurrency treasury company...

Follow-Up: Sana Biotechnology 6-Month Data, +150 % Rally, and Morgan Stanley's New Overweight Call In a public post in May, I wrote about Sana Biotechnology, Inc. (NASDAQ:SANA), a biotech that has developed a potential cure for type 1 diabetes. Here's an update on developments since. 1. Quick...

AstraZeneca Plc (NASDAQ:AZN) on Monday released topline data from the BaxHTN Phase 3 trial of baxdrostat in patients with uncontrolled or treatment-resistant hypertension. The trial included patients who were treated with two different antihypertensive medications and patients with resistant...

MiNK Therapeutics, Inc. (NASDAQ:INKT) stock is trading higher on Friday, with a session volume of 20.2 million compared to the average volume of 7.5 million as per data from Benzinga Pro. The clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf invariant natural killer T (...

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) moved closer to potential FDA approval for its Cardamyst (etripamil) nasal spray, an investigational therapy for paroxysmal supraventricular tachycardia (PSVT), as the U.S. Food and Drug Administration (FDA) accepted the company’s response to prior...

Capricor Therapeutics Inc. (NASDAQ:CAPR) stock is trading lower on Friday. The company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for Deramiocel, the company’s lead cell therapy candidate for...

The Delaware Supreme Court has overturned a lower court’s decision that allowed expert testimony supporting plaintiffs’ claims in a high-profile case alleging that Zantac, or its generic ranitidine, can cause cancer. The justices concluded that the trial court applied an incorrect legal...

Above Food Ingredients Inc (NASDAQ:ABVE) experienced a surge of 129.68%  in its stock price after hours on Monday.  What Happened: Following a staggering rise of 335.39% to $1.55 during regular trading hours, the plant-based food company founded in Canada continued to increase after the...

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (OTC:ALPMF) (OTC:ALPMY) on Thursday released topline results from the overall survival (OS) analysis from the Phase 3 EMBARK study evaluating Xtandi (enzalutamide), in combination with leuprolide and as a monotherapy, in men with non-metastatic...

IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation Inc., and AbbVie Inc. (NYSE:ABBV), on Thursday, announced an exclusive licensing agreement for IGI’s lead investigational asset, ISB 2001, developed using IGI’s proprietary BEAT protein platform...

The U.S. Food and Drug Administration (FDA) has approved Moderna Inc.’s (NASDAQ:MRNA) supplemental Biologics License Application (sBLA) for Spikevax, the company’s COVID-19 vaccine, in children six months through 11 years of age who are at increased risk for COVID-19 disease. The...